arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Protalix BioTherapeutics, Inc.

PLX
$2.83 ▲ +0.07 (+2.54%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Protalix BioTherapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $226.4M
Dividend Yield
Revenue Growth 27.1%
Op. Margin 23.5%
ROIC 5.1%
FCF / Share $-0.14
Trailing P/E 56.6x
Price / Book 3.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.90M
↑ +27.1%
Net Income Profit after all expenses
$3.78M
↑ +2203.0%
Operating Margin Operating profit as % of sales
23.5%
↓ -62.5% 15th
FCF / Share Free cash flow per share
$-0.14
↓ -90.9%
Long-Term Debt Long-term obligations
$376.00K
↓ -86.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
12
Returns
31
Cash Quality
87

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters